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Abstract
Background: The constitutive hyper-activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/
mammalian target of rapamycin (mTOR) signaling pathways has frequently been associated with acute myeloid
leukemia (AML). While many inhibitors targeting these pathways have been developed, the anti-leukemic effect
was not as robust as expected. As part of the molecular link between PI3K/Akt and mTOR kinase, the role of Rheb1
in AML remains unexplored. Our study aims to explore the role of Rheb1 in AML and estimate whether Rheb1
could be a potential target of AML treatment.
Methods: The expressions of Rheb1 and other indicated genes were analyzed using real-time PCR. AML mouse
model was established by retrovirus transduction. Leukemia cell properties and related signaling pathways
were dissected by in vitro and in vivo studies. The transcriptional changes were analyzed via gene chip analysis.
Molecular reagents including mTOR inhibitor and mTOR activator were used to evaluate the function of related
signaling pathway in the mouse model.
Results: We observed that Rheb1 is overexpressed in AML patients and the change of Rheb1 level in AML patients
is associated with their median survival. Using a Rheb1-deficient MLL-AF9 murine AML model, we revealed that
Rheb1 deletion prolonged the survival of AML mice by weakening LSC function. In addition, Rheb1 deletion
arrested cell cycle progression and enhanced apoptosis of AML cells. Furthermore, while Rheb1 deletion reduced
mTORC1 activity in AML cells, additional rapamycin treatment further decreased mTORC1 activity and increased
the apoptosis of Rheb1Δ/Δ AML cells. The mTOR activator 3BDO partially rescued mTORC1 signaling and inhibited
apoptosis in Rheb1Δ/Δ AML cells.
Conclusions: Our data suggest that Rheb1 promotes AML progression through mTORC1 signaling pathway and
combinational drug treatments targeting Rheb1 and mTOR might have a better therapeutic effect on leukemia.
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Background
As the most common acute leukemia in adults, acute
myeloid leukemia (AML) is a genetically heterogeneous
neoplasm. Although this disease can initially be con-
tained using classical chemotherapy, AML frequently re-
lapses during the course of the disease [1]. The leukemia
cells can be influenced by microenvironmental cues and
also affect the normal niche of hematopoietic stem cells
(HSCs) [2, 3]. A small fraction of AML cells can self-
renew and are thus referred to as leukemic stem cells
(LSCs). LSCs share properties with normal HSCs in sus-
taining normal hematopoietic hierarchy [4, 5]. LSCs have
been implicated in the relapse of leukemia and are ex-
tensively studied as potential therapeutic targets. The
signaling pathways that regulate the development and
survival of these cells are of particular interest [5, 6].
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Mammalian target of rapamycin (mTOR) is an evolu-
tionarily conserved serine/threonine (Ser/Thr) kinase that
senses and responds to multiple signals in eukaryotes.
mTOR interacts with multi-proteins to form two distinct
complexes, designated mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2). mTORC1 primarily com-
prises mTOR, raptor, PRAS40, deptor, the Tti/Tel com-
plex, and mLST8. This complex directly phosphorylates
p70 ribosomal protein S6 kinase 1 (p70S6K1, phosphory-
lates ribosomal protein S6) and eukaryote translation initi-
ation factor 4E binding protein 1 (4E-BP1) to regulate cell
growth and survival [7]. Upon growth factor/cytokine
stimulation, phosphatidylinositol 3-kinase (PI3K) is rapidly
activated and recruits protein kinase B (Akt, PKB) to the
plasma membrane. Akt is subsequently phosphorylated at
its T308 and S473 sites. Following the phosphorylation of
Akt or ERK1/2, TSC1/TSC2 is destabilized and the
inhibition of mTOR signaling is relieved. The activation of
the PI3K/Akt/mTOR signaling pathway has frequently
been reported in AMLs [8, 9]. For example, a previous
study showed that TSC1 deficiency disrupts the quies-
cence and long-term reconstitution of HSCs, reflecting
over-activated mTORC1 [10]. The deletion of phosphatase
and tensin homologue (PTEN), which negatively regulates
the PI3K/Akt/mTOR pathway, leads to leukemia, includ-
ing AML in mice [11]. In addition, the deletion of raptor,
an essential component of mTORC1, suppresses AML
progression through the enhanced apoptosis of AML cells
[12]. Rapamycin, a natural mTOR kinase inhibitor, inhibits
not only the generation but also the maintenance of
leukemia in PTEN-evoked leukemogenesis [11]. Human
AMLs have also been shown to respond to rapamycin
[13], but with low efficacy, and new homologues of rapa-
mycin (rapalogs) are being developed to treat AMLs [14].
Ras homologue enriched in the brain (Rheb) is an acti-
vator of mTORC1 [15, 16]. Two Rheb family members,
Rheb1 (the original Rheb, hereafter referred to as Rheb1)
and Rheb2 (also known as RhebL1), have been identified
in mammals. Rheb1 is essential for murine development,
as the loss of Rheb1 results in embryonic death at
approximately midgestation [17], while Rheb2 is dis-
pensable in mouse development [18]. The TSC complex,
comprising TSC1, TSC2, and TBC1D7, are GTPase-
activating proteins (GAPs) of Rheb [19–21]. Active Rheb
might indirectly inhibit PI3K and mTORC2 signaling
through the induction of various mTORC1-dependent
negative feedback loops [22]. Previous studies have dem-
onstrated that Rheb1 was overexpressed in various can-
cers, such as non-small cell lung cancer, liver cancer,
bladder cancer, and prostate cancer [23–26]. The high
level of Rheb1 was associated with the progression, me-
tastasis, drug resistance, and poor prognosis of breast
cancer patients [27]. The human cancer genome data
analysis revealed recurrent mutations in Rheb1 [28]. In
addition, Rheb1 overexpression also favors myc-mediated
lymphomagenesis in a mouse model [29]. The findings in-
dicate that Rheb1 contributes to tumorigenesis and might
be a potential treatment target.
Although it has been clearly established that the dys-
regulation of mTORC1 promotes leukemogenesis, the
role of Rheb1 in the development and maintenance of
AML is not clear. In the present study, we examined the
role of Rheb1 in the MLL-AF9 murine AML model and
showed that Rheb1 deletion suppressed AML progres-
sion by impairing LSC function and reducing mTORC1
signaling.
Results
Rheb1 is overexpressed in human AMLs
Previous studies have demonstrated that the PI3K/Akt/
mTOR signaling pathway is involved in many cancers,
including AMLs, thus implicating a role for Rheb1 in can-
cer progression/maintenance. Here, we used a curated
database (the HemaExplorer, http://servers.binf.ku.dk/
hemaexplorer), which provides gene expression profiles of
processed mRNA, to analyze the mRNA expression level
of Rheb1 in human AML. We observed that Rheb1
mRNA expression was substantially higher in human
AMLs, such as AML with t(8;21)(AMLI_ETO), AML with
t(15;17)(APL), AML with inv(16)/t(16;16), or AML with
t(11q23)/MLL in contrast to normal polymorphonuclear
cells (PMN) in the peripheral blood (PB) or bone marrow
(BM) (Fig. 1a). Interestingly, Rheb1 mRNA overexpression
was also confirmed in human AML CD34+ cells compared
with normal CD34+ cells. We observed that Rheb1 mRNA
expression was increased in human AML CD34+ cells
compared with normal CD34+ cells (Fig. 1b). In addition,
AML patients with higher Rheb1 expression showed re-
duced survival (median survival: 8.47 months) compared
with patients with lower Rheb1 expression (median
survival: 11.47 months) based on the Leukemia Gene
Atlas (LGA) analysis (http://www.leukemia-gene-atlas.-
org/LGAtlas/LGAtlas.html#aboutUs) (Additional file 1:
Figure S1A) [30]. We further accessed The Cancer
Genome Atlas (TCGA) data via the cBioPortal for Can-
cer Genomics (http://www.cbioportal.org/public-portal)
[31]. We found that AML patients with Rheb1 deletion
showed increased survival (median survival: 18.96 months)
compared with patients without Rheb1 deletion (median
survival: 15.01 months) (Additional file 1: Figure S1B).
These indicate that Rheb1 is a risk factor for AML.
Rheb1 deletion suppresses AML progression in vivo
To assess the role of Rheb1 in AML, we first examined
Rheb1 expression in the BM of wild-type (WT) mice
and established MLL-AF9-induced AML mice by
Western blotting analysis and found that Rheb1 protein
was overexpressed in AML mice in comparison with
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WT mice (Additional file 1: Figure S2A). To further
investigate the role of Rheb1 in murine AML, we first
generated Vav1-Cre;Rheb1fl/fl (Rheb1Δ/Δ) mice via cross-
ing Vav1-Cre mice with Rheb1fl/fl mice. Lineage-negative
(Lin−) cells were isolated from Rheb1fl/fl (control) or
Rheb1Δ/Δ mice and subsequently transduced with the
MLL-AF9-GFP fusion gene. These genetically modified
GFP+ cells were subsequently sorted and transplanted
into lethally irradiated syngeneic recipients to generate
MLL-AF9-induced Rheb1fl/fl or Rheb1Δ/Δ AML mice,
respectively. The GFP+ cells were expanded three times
in serial transplantations prior to analysis as depicted
in Fig. 2a. Both recipient mice developed AML, and
flow cytometric analysis showed that GFP+ cells were
B220− CD3−CD11b+ (Additional file 1: Figure S2B). The
Rheb1 gene was efficiently deleted in Rheb1Δ/Δ GFP+ cells
as demonstrated by RT-PCR analysis (Additional file 1:
Figure S2C) and PCR (Additional file 1: Figure S2D).
To determine the role of Rheb1 in AML, we intraven-
ously injected Rheb1fl/fl or Rheb1Δ/Δ GFP+ P2 or P3 cells
(see “Methods” section) into sublethally irradiated recipi-
ent mice. We observed that Rheb1 deletion significantly
prolonged the survival of AML mice compared with the
control in both P2 and P3 groups. The survival of
Rheb1Δ/Δ GFP+ P3-recipient mice was much longer than
that of P2-recipient mice, and the following experiments
were performed using P3 cells in mice (Fig. 2b, c).
Consistent with the less leukemia burden in Rheb1Δ/Δ
AML mice, the number of WBCs in the PB of Rheb1Δ/Δ
AML mice was significantly decreased, while the platelet
(PLT) counts were increased compared with that of
control AML mice (Fig. 2d, e). Decreased percentages of
GFP+ cells in the PB, BM, and spleen were also evident
in Rheb1Δ/Δ AML mice in contrast with that in the
controls (Fig. 2f–h). In addition, the spleen size in
Rheb1Δ/Δ AML mice was smaller, and the spleen
weight (mg) to body weight (g) ratio was significantly
decreased in Rheb1Δ/Δ AML mice compared with the
controls (Fig. 2i). Consistent with this finding, less
AML cells were observed in histological section of
the spleens obtained from Rheb1Δ/Δ AML mice com-
pared with the control (Additional file 1: Figure S2E),
indicating less infiltration of Rheb1Δ/Δ GFP+ cells in
the spleen. Therefore, Rheb1 deficiency significantly
suppressed AML progression in vivo and prolonged
the life span of AML mice.
Rheb1 deficiency impairs LSC function
Previous studies using MLL-AF9 AML models have
established that LSCs are enriched in c-Kit+Gr-1− (K+G−)
[6] or L-GMP populations [32]. To further delineate
AML progression without Rheb1, the differentiation
status of Rheb1fl/fl or Rheb1Δ/Δ AML cells was ana-
lyzed using the cell surface markers, c-Kit and Gr-1.
We observed that the percentage of K+G− cells was
slightly increased, whereas the percentage of K+G+
cells was decreased, and the percentage of K−G+ cells
was not different in the BM of Rheb1Δ/Δ GFP+ cells
compared with the control (Fig. 3a). Although the ab-
solute cell number of K+G− and K−G+ cells was not
increased, the number of K+G+ cells in the BM was













































































































Fig. 1 Rheb1 is overexpressed in human AML. a Rheb1 mRNA expression in human AML cells with t(8;21)(AMLI_ETO), t(15;17)(APL), inv(16)/
t(16;16), and t(11q23)/MLL using the HemaExplorer database. b Rheb1 mRNA expression in human AML and normal CD34+ cells. The data
were analyzed using the Mann-Whitney U test. The significance is indicated with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001)
Gao et al. Journal of Hematology & Oncology  (2016) 9:36 Page 3 of 14
(Fig. 3b). The L-GMP (Linlow GFP+ c-Kit+ FcR-γ+ CD34+)
frequency was subsequently analyzed, and no difference in
the L-GMP frequency was observed between the two
groups (Additional file 1: Figure S2F and Fig. 3c), consist-
ent with the frequency of K+G− cells (Fig. 3b). In addition,
the percentages of L-GMP and K+G− cells in the
spleen were also not changed between the two groups
(Additional file 1: Figure S2G and H). These results
indicate that the Rheb1 deletion did not affect the ab-
solute number of LSCs in the BM.
To determine whether the prolonged survival of
Rheb1Δ/Δ AML mice was due to impaired homing ability
of AML cells, Rheb1fl/fl or Rheb1Δ/Δ GFP+ cells were
transplanted into lethally irradiated recipient mice. The
recipient mice were sacrificed at 24 h after transplant-
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Fig. 2 Rheb1 deletion prolongs the survival of AML mice. a Experimental scheme of the Rheb1-deficient MLL-AF9 mouse model. b The survival
curve of Rheb1fl/fl and Rheb1Δ/Δ AML mice using Kaplan-Meier analysis (n = 11). Approximately 5 × 105 P1 GFP+ cells from the two groups were
transplanted into sublethally irradiated recipient mice (P2). c The survival curve of Rheb1fl/fl and Rheb1Δ/Δ AML mice calculated using Kaplan-Meier
analysis (n = 6). Approximately 1 × 106 P2 GFP+ cells obtained from the two groups were transplanted into sublethally irradiated recipient mice
(P3). d The number of white blood cells (WBC) in PB (n = 4). e The number of platelets (PLT) in PB (n = 4). PB samples were obtained from AML
mice when Rheb1fl/fl GFP+ cells in PB was approximately 80 %. f–h The percentage of GFP+ cells in the PB (f), BM (g), and spleen (h) of Rheb1fl/fl
and Rheb1Δ/Δ AML mice by FACS analysis (n = 4). i The spleen size (left) and spleen weight to body weight ratio of Rheb1fl/fl and Rheb1Δ/Δ
AML mice (right). All experiments were performed at least three times. The values in the panels represent the mean numbers ± SEM. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001
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AML cells. The absolute number of GFP+ cells homing
to the BM and spleen was not changed between the two
groups (Additional file 1: Figure S3A), indicating that
homing is not a factor underlying the prolonged survival
of Rheb1Δ/Δ AML mice.
To explore the transcriptional landscape changes that
distinguish Rheb1fl/fl or Rheb1Δ/Δ AML cells, gene ex-
pression microarray was performed with sorted Rheb1fl/fl
or Rheb1Δ/Δ GFP+ cells. The deletion of Rheb1 in sorted































































































































































































































































Fig. 3 Rheb1 deletion impairs LSC function. a The differentiation profile of AML cells (left) and the percentages of subpopulations (right) using
c-Kit and Gr-1 surface markers (n = 4). b The absolute number of these subpopulations in the BM (n = 4). c The absolute number of L-GMPs in the
BM (n = 4). d, e The enrichment of selected gene targets for HOXA9 and MEIS1, NUP98-HOXA9 fusion genes (d), and HSC downregulation-related
genes (e). The NES (normalized enrichment score) and P values are indicated in each plot. f The mRNA expression of the indicated genes
assessed using RT-PCR. g, h Colony formation of GFP+ AML cells (g) and GFP+ K+G− AML cells (h) that were sorted, replated in semisolid
medium, and cultivated for 8 days prior to counting. The data show the mean colony numbers ± SEM. All experiments were performed
at least three times. The data represent the mean numbers ± SEM. i The survival curve of Rheb1fl/fl and Rheb1Δ/Δ AML mice using Kaplan-
Meier analysis (n = 6). Approximately 1000 P3 K+G− cells from the two groups were transplanted into sub-lethally irradiated recipient mice
(P4). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001
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mRNA expression levels in these cells using RT-PCR
(data not shown). Gene set enrichment analysis (GSEA)
[33] revealed the significant enrichment of downregu-
lated genes in hematopoietic precursor cells expressing
HOXA9 and MEIS1, CD34+ hematopoietic cells express-
ing the NUP98-HOXA9 fusion (Fig. 3d), and CD133+
hematopoietic stem cells (as an alternative for CD34+
cells) (Fig. 3e). The enriched and selected genes were
further validated by RT-PCR. HOXA9, which is required
for the survival of MLL-arranged acute leukemia, is
overexpressed in approximately 50 % of AML and highly
associated with poor prognosis [34, 35]. Here, we ob-
served that the HOXA9 expression level decreased due
to Rheb1 deletion (Fig. 3f ). The mRNA expressions of
TGFβ1, MMP8 (matrix metalloproteinase 8), and LTF
(lactoferrin), which all show tumor suppressing ability
[36–38], were significantly increased in Rheb1Δ/Δ GFP+
cells compared with the control (Fig. 3f ). This result
suggests that Rheb1 deletion contributes to AML pro-
gression through the downregulation of HOXA9
expression and the upregulation of tumor suppressor
gene expression, which potentially affects LSC function.
To further investigate the effect of Rheb1 deletion on
LSC function, we examined the colony-forming ability of
Rheb1fl/fl and Rheb1Δ/Δ AML cells to characterize the
progression and stemness of AML cells. The sorted
GFP+ or K+G− cells were cultured in methylcellulose
medium supplemented with IL-3, IL-6, SCF, and GM-
CSF, and the colonies were counted after 7 to 8 days
of culture. A previous study established that colonies
show progression in AML cell maturation from type
A to type B to type C, demonstrating a progressive
loss of stemness [39]. Here, we observed that the
number of total colonies was significantly decreased
in Rheb1Δ/Δ GFP+ cells compared with the control.
Interestingly, the number of type A colonies was re-
duced, while the number of type B and type C col-
onies was increased (Fig. 3g). Similar observations
were obtained with Rheb1Δ/Δ K+G− cells compared
with the control (Fig. 3h). Furthermore, K+G− cell
transplantation showed that the survival of Rheb1Δ/Δ
AML mice was significantly prolonged than the con-
trol mice (Fig. 3i). These results supported that the
loss of Rheb1 impaired AML progression and affected
the stemness of AML cells.
Rheb1 deficiency arrests more AML cells in the G0 phase
To explore the mechanism by which Rheb1 promotes
AML progression, we performed gene ontology (GO)
enrichment analysis of the 1487 differentially expressed
genes derived from the microarray expression data
(Additional file 1: Figure S3B). The analysis indicated
that “negative regulation of cell cycle” and “apoptotic
signaling pathway” categories were upregulated, while
the “cell cycle” category was downregulated (Fig. 4a).
Because cancer progression is determined by the rate
of cell proliferation and death [40], GSEA was used to
analyze cell cycle and apoptosis-related gene sets. We
observed that genes associated with cell cycle processes
(Fig. 4b) and the M phase of the mitotic cell cycle
(Additional file 1: Figure S3C) were enriched in control
AML cells. Flow cytometric analysis of the cell cycle sta-
tus of fresh BM GFP+ cells using Ki-67 and Hoechst
33342 staining revealed an increased proportion of cells
in the G0 phase and a decreased proportion of cells in
the G1 and S/G2/M phases of Rheb1Δ/Δ GFP+ cells and
its corresponding subpopulations (K+G− cells and K+G+
cells) (Fig. 4c, d and Additional file 1: Figure S3D). Inter-
estingly, the Rheb1 deletion had no effect on the cell
cycle status of K−G+ cells (Additional file 1: Figure S3E).
Since cell cycle progression is controlled through various
regulators, such as cyclins, cyclin-dependent kinases
(CDKs) [41], and CDK inhibitors (CKIs) [42], we also ex-
amined the expression of these genes and observed that
the mRNA expressions of p18, p21, p27, and p57 were
increased in Rheb1Δ/Δ GFP+ cells compared with control
(Fig. 4e), while the mRNA expression of cyclin G2, a
negative regulator of cell cycle progression [43], was also
upregulated in Rheb1Δ/Δ GFP+ cells compared with
control (Additional file 1: Figure S3F). These findings
suggest that Rheb1 might promote AML cell cycle pro-
gression through the inhibition of the transcription of
CKIs and cyclin G2. Furthermore, in Rheb1Δ/Δ K+G−
cells, the mRNA expression of p57 was upregulated
compared with control (Fig. 5e and Additional file 1:
Figure S3G). Therefore, Rheb1 promotes LSC cell
cycle progression probably via the inhibition of p57
transcription.
Rheb1 deletion induces the apoptosis of LSC cells
BM GFP+ cells were sorted and cultured, and the apop-
tosis status was examined at 72 h after culture through
flow cytometry using 7-AAD and annexin V. The per-
centage of apoptotic GFP+ cells (annexin V+) in the BM
was increased (Fig. 4g), and the proportions of apoptotic
K+G−, K+G+, and K−G+ cells (annexin V+) were also sig-
nificantly increased in Rheb1-deficient AML cells com-
pared with the control (Fig. 4h). Apoptosis is regulated
by anti-apoptotic signals, including Mcl-1, and pro-
apoptotic signals, including Puma, Bim, Bax, and Bak
[44]. While the p53 tumor suppressor inhibits cell
growth through both the inhibition of cell cycle progres-
sion and the activation of apoptosis, the latter is consid-
ered to be essential for the tumor suppressor ability of
this protein [45]. To explore the potential cause of
apoptosis changes, we examined the mRNA expression
of these genes. Although we observed no obvious
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difference in the mRNA expression in Rheb1Δ/Δ and WT
GFP+ cells (Fig. 4i), the mRNA expression of p53 and
Bax was significantly increased in Rheb1Δ/Δ K+G− cells
compared with the WT control (Fig. 4j), suggesting that
Rheb1 inhibits the apoptosis of AML LSC cells through
the repression of the mRNA expression of p53 and Bax.
Fig. 4 Rheb1 deletion arrests cell cycle progression and increases the apoptosis of AML cells. a Upregulated (left) and downregulated (right) GO
terms of differentially expressed genes in Rheb1Δ/Δ GFP+ cells vs. the WT control. b Enrichment of the cell cycle process. NES (normalized enrichment
score) and P values are indicated in each plot. c, d The cell cycle status of GFP+ (c) and K+G− cells (d), n = 4. e, f GFP+ cells (e) and K+G− cells (f) were
sorted, and their RNAs were isolated for indicated gene analysis using RT-PCR. The data represent the mean numbers ± SEM. g, h The apoptosis
status of GFP+ (g) and K+G− cells (h), n = 4. i, j GFP+ cells (i) and K+G− cells (j) were sorted, and RNAs were isolated and analyzed using RT-PCR for the
indicated genes. The data represent the mean numbers ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001
















































































































































































































































































































Fig. 5 (See legend on next page.)
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Rheb1 deletion suppresses AML progression via mTORC1
signaling pathway
Because Rheb1 directly activates mTORC1, the mTORC1
function was evaluated based on the phosphorylation
levels of its downstream targets (S6 and 4E-BP1) using
flow cytometry in Rheb1Δ/Δ AML cells. As expected, the
phosphorylation levels of S6 and 4E-BP1 in GFP+ cells
and corresponding subpopulations (including K+G−,
K+G+, and K−G+ cells) were significantly decreased
in Rheb1Δ/Δ AML cells compared with the control
(Fig. 5a–d and Additional file 1: Figure S3H and I).
These findings indicate that the reduced progression
of AML in Rheb1Δ/Δ cells might be attributed to at-
tenuated mTORC1 activity.
We subsequently analyzed the HemaExplorer database
and observed that mTOR mRNA was indeed overex-
pressed in AML with inv(16)/t(16;16) and AML with
t(11q23)/MLL compared with PMN in the PB and BM
(Additional file 1: Figure S4A). In addition, the 4E-BP1
mRNA was also overexpressed in these AMLs, although
the S6 mRNA expression level in AML was not available
from the datasets (Additional file 1: Figure S4B). The
consistency of the overexpression of Rheb1, mTOR, and
4E-BP1 mRNA in these AML suggests that AML pro-
gression is clinically associated with Rheb1-regulated
mTORC1 signaling. Interestingly, mTOR was not all
overexpressed in the AML types in these datasets, sug-
gesting the potential involvement of other signaling
pathway(s) in AML (Additional file 1: Figure S4A). In
addition, phagosome and Jak-stat signaling pathways
were enriched in upregulated pathways in the KEGG
analysis (Additional file 1: Figure S4C) (http://
www.genome.jp/kegg/), while the p53 signaling path-
way and cell cycle were enriched in downregulated path-
ways in KEGG analysis (Additional file 1: Figure S4D).
To further evaluate the extent of how Rheb1 regulates
AML progression through mTORC1 signaling, BM GFP
+ cells were sorted and cultured for 24 h prior to rapa-
mycin addition. At 48 h after rapamycin treatment, the
apoptosis status of GFP+ cells and the S6 and 4E-BP1
phosphorylation levels were assessed by flow cytometry.
We observed that Rheb1-deficient GFP+ cells have
increased apoptosis rates under the mock treatment (no
rapamycin, with ethanol only, will also be referred as the
control), consistent with the findings in Fig. 4g. Signifi-
cantly, the apoptosis of both Rheb1fl/fl and Rheb1Δ/Δ
GFP+ cells was enhanced under rapamycin treatment
(Fig. 5e). To investigate whether the increased apoptosis
of AML cells reflected mTORC1 inhibition through
rapamycin, the S6 and 4E-BP1 phosphorylation levels
were examined. We observed that the phosphorylation
levels of S6 and 4E-BP1 in Rheb1Δ/Δ GFP+ cells were
lower than in Rheb1fl/fl GFP+ cells under the control
treatment (Fig. 5f ), consistent with the findings shown
in Fig. 5a. Rapamycin treatment decreased both S6 and
4E-BP1 phosphorylation levels in both Rheb1fl/fl and
Rheb1Δ/Δ GFP+ cells compared with their corresponding
controls, respectively (Fig. 5f ). These findings indicated
that mTORC1 protected AML cells from apoptosis and
Rheb1 inhibited AML cells apoptosis through mTORC1.
Interestingly, the phosphorylation level of S6 and 4E-
BP1 in Rheb1Δ/Δ GFP+ cells were further decreased after
rapamycin treatment compared with the control
(Fig. 5f ), indicating that Rheb1 is partially respon-
sible for mTORC1 signaling in AML cells.
3-Benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-
2(3H)-one (3BDO), a small molecular compound, has
been demonstrated to be a novel mTOR activator
that can significantly increase the phosphorylation of
RPS6KB1 and EIF4EBP1 in HUVECs [46]. To examine
how leukemia cells response to the rescued mTORC1
signaling, BM GFP+ cells (with or without Rheb1)
were sorted and cultured for 24 h prior to 3BDO
addition. At 48 h after 3BDO treatment, the S6 and
4E-BP1 phosphorylation levels and the apoptosis status of
GFP+ cells were assessed by flow cytometry. We ob-
served that 3BDO increased the S6 and 4E-BP1 phos-
phorylation of Rheb1Δ/Δ GFP+ cells (Fig. 5g). The
apoptosis of Rheb1Δ/Δ GFP+ cells was reduced significantly
under 3BDO treatment in comparison to Rheb1Δ/Δ GFP+
cells with vehicle (DMSO) treatment but not to the same
level as Rheb1fl/fl GFP+ cells with vehicle treatment
(Fig. 5h), indicating a partial reversal of increased
apoptosis due to loss of Rheb1.
(See figure on previous page.)
Fig. 5 Rheb1 deletion reduces mTORC1 signaling in AML cells. a FACS analysis of p-S6 in GFP+ cells. GFP+ cells were sorted from fresh BM cells.
The left panel shows the mean fluorescent intensity (MFI) of both groups, the right panel shows the normalized MFI of these groups (n = 4). IgG
was used as an internal control. b The normalized MFI of p-S6 in the LSC cells of the two groups (n = 4). c FACS analysis of p-4E-BP1 in GFP+ cells.
GFP+ cells were sorted from fresh BM cells. The left panel shows the mean fluorescent intensity (MFI) of both groups, and the right panel shows
the normalized MFI of these groups (n = 4). IgG was used as an internal control. d The normalized MFI of p-4E-BP1 in the LSC cells of the two
groups (n = 4). e The percentage of apoptotic GFP+ cells treated with mock treatment (absolute ethanol without rapamycin, vehicle), and
rapamycin was dissolved in absolute ethanol (EtOH) (n = 3). The data represent the mean numbers ± SEM. f The normalized MFI (Log10) of p-S6
in cultured GFP+ cells of the two groups treated with EtOH without rapamycin (n = 3). g The normalized MFI (Log10) of p-S6 in cultured GFP+
cells of the two groups treated with DMSO without 3BDO (n = 3). h The percentage of apoptotic GFP+ cells treated with mock treatment
(DMSO without 3BDO, vehicle), and 3BDO was dissolved in DMSO (n = 3). i The Rheb1/mTORC1 signaling pathway in AML progression. *P < 0.05;
**P < 0.01; ***P < 0.001; ****P < 0.0001
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Discussion
Rheb1 has been demonstrated as a molecular link be-
tween upstream PI3K/Akt signaling and downstream
mTOR kinase to regulate cell growth [16, 47]. The
PI3K/Akt/mTOR signaling pathway has been demon-
strated to play numerous vital roles in cell survival and
cell metabolism [48, 49]. The constitutive activation of
PI3K/Akt/mTOR signaling was observed in 50–80 % of
AML patients and has been associated with poor prog-
nosis [50, 51]. Many inhibitors targeting this signaling
pathway, either alone or in combination, have been de-
veloped, but with mediocre anti-leukemic efficacy [52].
Although Rheb1 has been shown to be mutated in
cancer [28], the role of Rheb1 in AML remains unex-
plored. Here, we observed that in human AMLs, Rheb1,
and mTOR mRNA were overexpressed (Fig. 1a and
Additional file 1: Figure S4A). Using a Rheb1-deficient
MLL-AF9 murine leukemia model, we further demon-
strated that Rheb1 positively regulates leukemic cell
growth via mTORC1 (Fig. 2b).
LSCs are composed of a minor subset of AML cells
that are responsible for leukemia initiation, progression,
and relapse [53]. LSCs are frequently insensitive to
chemotherapy and therefore considered potential thera-
peutic targets for the eradication of cancer [54]. In the
present study, the Rheb1 deletion did not change the
LSC number in mouse BM, but the lifespan of AML
mice was significantly prolonged. Additional experi-
ments revealed that more Rheb1-deficient AML cells
were arrested in the G0 phase with several upregulated
CKIs. GSEA showed the enrichment of downregulated
genes in hematopoietic progenitor or stem cells in
Rheb1Δ/Δ GFP+ cells, and some of these selected genes
were confirmed by RT-PCR (Fig. 3d–f). In addition,
Rheb1Δ/Δ LSCs showed reduced colony formation, and the
colonies exhibited reduced stemness in vitro (Fig. 3g, h).
Furthermore, LSC transplantation showed Rheb1 deletion
significantly prolonged the survival of AML mice in vivo
(Fig. 3i). Thus, Rheb1 is required for LSC functional
maintenance and AML progression. LSCs are known
to resemble HSCs that give rise to all lineages of
blood cells [55]. Interestingly, we found that under
steady condition, Rheb1 deletion in hematopoietic
system impaired HSC self-renewal and differentiation
capability (data not shown) as in Rheb1Δ/Δ LSCs.
Apoptosis is considered a key process for cancer
progression or remission. Although apoptotic signaling
circuitry in mammals is complicated and redundant with
multiple regulators and effectors, this process offers at-
tractive novel therapeutic targets along the pathway [40].
Here, we showed that the Rheb1 deletion increased the
proportion of apoptotic AML cells, including LSCs,
coincident with the upregulation of p53 and Bax mRNA
expression (Fig. 4g–j). The enhanced apoptosis of
Rheb1Δ/Δ LSCs was further confirmed based on the ob-
servation that GFP+ cells and LSCs showed reduced p-
4E-BP1, indicating the induction of apoptosis in tumor
cells [56] and suggesting that Rheb1 might be a potential
drug target for LSCs.
As a direct downstream effector of Rheb1, mTORC1 is
essential for cell growth and metabolism. The deletion
of raptor, a core component of mTORC1 [57], in the
MLL-AF9 murine leukemia model, inhibited mTORC1
activity as evidenced by the decreased phosphorylation
of S6 and 4E-BP1, decreased proliferation, and enhanced
apoptosis of AML cells. These resulted in the prolonged
survival of raptor-deficient AML mice, although the LSC
number was increased in the raptor-deficient AML
mouse model [12]. The discrepancy in LSC numbers in
Rheb1- and raptor-deficient AML mouse models likely
reflects the extent of mTORC1 inhibition. Indeed, we
found that rapamycin treatment further decreased the
phosphorylation level of S6 and 4E-BP1 and enhanced
apoptosis in Rheb1Δ/Δ GFP+ cells (Fig. 5e, f ), while
mTOR activator 3BDO increased the mTORC1 signal,
partially rescued the augmented apoptosis of Rheb1Δ/Δ
GFP+ cells (Fig. 5g, h). Additionally, microarray analysis
also showed that several mTORC1-independent path-
ways were also significantly altered (Additional file 1:
Figure S4C and D). All these suggest the involvement of
either a non-canonical Rheb1 pathway or the indirect ef-
fects resulting from the loss of Rheb1 [58, 59].
Despite advances in the current understanding of AML,
the development of clinically effective therapies to eradi-
cate AMLs has shown limited success, likely reflecting the
existence of LSCs. Here, we convincingly showed that
rapamycin could further enhance apoptosis in Rheb-
deficient AML or LSC cells, suggesting the combinational
use of Rheb1-specific inhibitors and improved rapalogs
that better target mTORC1 might eradicate LSCs in AML
patients with higher Rheb1 or mTORC1 levels.
Conclusions
Rheb1 is overexpressed in human AML. Rheb1 deletion
prolongs the survival of AML mice by reducing
mTORC1 signaling and increasing apoptosis in AML
cells. Rapamycin could further reduce mTORC1 signal-
ing and increase the apoptosis of Rheb1Δ/Δ GFP+ cells,
while 3BDO partially rescues the apoptosis of Rheb1Δ/Δ
GFP+ cells through the activation of mTORC1 pathway
(Fig. 5i). Our study thus suggests that combinational
therapy targeting both Rheb1 and mTORC1 might be
more efficient in eradicating leukemia.
Methods
Mice and genotyping
Rheb1fl/fl mice were a kind gift from Dr. Bo Xiao [18].
Transgenic mice expressing Cre recombinase under the
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control of the Vav1 promoter (Vav1 Cre) were pur-
chased from the Jackson Lab. The Rheb1fl/fl mice were
crossed with Vav1-Cre mice to generate the specific de-
letion of Rheb1 in the hematopoietic system. The Vav1-
Cre;Rheb1fl/fl (Rheb1Δ/Δ) genotype was determined using
PCR with the following primers to identify Rheb1fl/fl or
Rheb1Δ/Δ mice: Rheb1, 5′-GCC CAG AAC ATC TGT
TCC AT-3′ and 5′-GGT ACC CAC AAC CTG ACA
CC-3′; Vav1-Cre, 5′-AGATGCCAGGACATCAGGAA
CCTG-3′ and 5′-ATCAGCCACACCAGACACAGA
GATC-3′. All animal protocols were approved by the
Institutional Animal Care and Use Committee (IACUC),
Institute of Hematology and Blood Diseases Hospital,
CAMS/PUMC. All surgeries were performed under so-
dium pentobarbital anesthesia, and all efforts were made
to minimize mouse suffering.
Human specimens
Normal human BM mononuclear cells (BM-MNCs)
were obtained from allogeneic transplantation donors at
the Institute of Hematology and Blood Diseases Hos-
pital, CAMS/PUMC. Primary human BM AML cells
were obtained from State Key Laboratory of Experimen-
tal Hematology, Institute of Hematology and Blood
Diseases Hospital, CAMS/PUMC. Specimen acquisition
was approved by Institutional Review Boards (IRB), State
Key Laboratory of Experimental Hematology, Institute
of Hematology and Blood Diseases Hospital, CAMS/
PUMC. All donors signed the informed consent forms.
The CD34+ cells were enriched using a CD34 Microbead
Kit (Miltenyi, German).
Establishment of the MLL-AF9 AML mouse model
MSCV-MLL-AF9-GFP plasmids were transduced into
293T cells to produce MLL-AF9 retroviruses using
Lipofectamine 2000 (Invitrogen). Lineage negative (Lin−)
cells were isolated from Rheb1fl/fl or Rheb1Δ/Δ mice and
infected with MLL-AF9 retroviruses. At 72 h after infec-
tion, GFP+ cells were sorted and intravenously injected
into lethally irradiated C57BL/6J-recipient mice. The
GFP+ cells of primary AML mice were obtained as P0
cells. P0 cells were intravenously injected into secondary
(P1) sub-lethally irradiated C57BL/6J-recipient mice to
expand leukemic cells until P2 generation and subse-
quently to P3 generation. All subsequent experiments
were performed using P3 cells.
Flow cytometry
Peripheral blood (PB) was obtained from either the tail
veins or retro-orbital bleeding of mice, and red blood
cells (RBCs) were lysed using ammonium chloride-
potassium bicarbonate buffer prior to staining. Bone
marrow (BM) cells were flushed out from the tibias, fe-
murs, and ilia using a 25-gauge needle with PBS
supplemented with 2 % fetal bovine serum (FBS) and
20 mM EDTA (abbreviated as PBE). The spleen cells
were suspended as a single cell suspension. The cells
were stained with antibodies purchased from either
eBioscience (San Diego, CA, USA) or BD Bioscience
(New Jersey, NJ, USA). For the analysis of intracellular
proteins, 1 × 106 GFP+ cells were sorted from fresh BM
cells. The sorted GFP+ cells were labeled with surface
antibodies, fixed with 4 % paraformaldehyde, and perme-
abilized with 0.1 % Triton X100, and subsequently
washed twice with 1 ml of cold PBE, resuspended with
cold PBS supplemented with 25 % FBS, and intracellu-
larly stained with antibodies against p-S6(Ser240/244)
and p-4EBP1(Thr37/46). The cells were analyzed using
flow cytometry. FlowJo software was used to analyze
the results.
For cell cycle analysis, fresh BM GFP+ cells were sorted,
labeled with surface antibodies, fixed and permeabilized
with BD IntraSure Kit (BD Bioscience), and then
intracellularly stained with antibodies against Ki67
(BD Bioscience) and Hoechst 33342 (Sigma-Aldrich).
For the apoptosis assay, BM GFP+ cells were sorted
from leukemic mice, cultured for 72 h in vitro and
labeled with surface antibodies, fixed and permeabilized
using the BD IntraSure Kit (BD Bioscience), and subse-
quently intracellularly stained with annexin V and 7-AAD
(BD Bioscience).
Mouse colony-forming cell assay (CFC)
GFP+ cells were sorted and cultured in methylcellulose
medium (catalog #03231, StemCell Technologies) con-
taining 50 ng/ml mSCF, 10 ng/ml mIL-6, 10 ng/ml mIL-
3, and 10 ng/ml mGM-CSF (all from Peprotech). The
sorted cells were cultured in 24-well plates at a volume
of 0.5 ml, with 300 cells. The colonies were counted
after 7–10 days of incubation.
Cell culture
BM GFP+ cells were sorted and cultured in IMDM
(Gibco) supplemented with 10 % FBS and 50 ng/ml
mSCF, 10 ng/ml mIL-6, and 10 ng/ml mIL-3 (all from
Peprotech, USA) for 24 h. The sorted cells were
cultured in 24-well plates at a volume of 1.0 ml, with
4 × 104 cells. After 24 h of culture, rapamycin (LC
Lab, USA) was added at a final concentration of
5.45 nM/ml or 3BDO (a kind gift from Dr. Junying
Miao) was added to the medium containing GFP+
cells at a final concentration of 30 nM/ml. The same
volume of absolute ethanol or DMSO was added to
the control group (vehicle group). At 48 h after drug
treatment, the cells were collected, and the apoptotic
status, and p-S6 and p-4E-BP1 levels were analyzed
through flow cytometry.
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Microarray analysis and human AML database
GFP+ cells were sorted using a BD FACS Aria III flow
cytometer, and RNAs were extracted with TRIzol reagent
(Invitrogen, Canada) and purified using the RNeasy Mini
Kit (Qiagen, German). Affymetrix GeneChip® Mouse
Transcriptome Assay 1.0 was performed to estimate the
whole transcriptome expression changes. The differen-
tially expressed genes were filtered as P < 0.05 and fold
change >1.2. The gene-set enrichment data were ana-
lyzed using GSEA, GO, and KEGG (FDR < 0.25, P <
0.05). The HemaExplorer (http://servers.binf.ku.dk/
hemaexplorer) is a curated database that provides the
gene expression profiles of processed mRNA from Hu-
man AMLs. We obtained the mRNA expression data
from the database, and the raw data were photographed
using GraphPad Prism 6.0.
Real-time PCR (RT-PCR)
Total RNA from GFP+ cells was extracted using the
RNeasy Mini Kit (Qiagen). First-strand cDNA was syn-
thesized with oligo (dT) primer according to the manu-
facturer’s instructions. The number of transgene copies
in the individual samples was determined by RT-PCR
(Stepone Fast Real-Time PCR system; Applied Biosys-
tems) using FastStart Universal SYBR Green PCR
Master mix (Roche). All primer sequences are listed
in Additional file 1: Table S1.
Statistical analysis
GraphPad Prism 6.0 and SPSS 21.0 statistical software
were used for statistical analyses. Kaplan-Maier survival
curves were constructed using GraphPad Prism 6.0, and
the log-rank (Mantel-Cox) analysis was used to analyze
the results. For bar graphs, the unpaired two-tailed
Student’s t test was used to compute the P values. P < 0.05
was considered significant. Significant differences are
indicated with asterisks (*P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001).
Additional file
Additional file 1: Figure S1. The correlation of Rheb1 expression level
with AML prognosis. (A) Kaplan-Meier event-free survival curves of AML
patients, with low (≤50 % quantile, n = 426) and high (>50 % quantile, n
= 3) expression based on Verhaak et al.’s dataset. (B) Kaplan-Meier overall
survival curves of AML patients, w/o Rheb1 deletion based on the
cBioPortal database. Figure S2. The genotype of established AML mouse
model. (A) Western blotting of Rheb1 protein level in WT and AML
cells (n = 3). (B) Flow cytometric analysis of AML cells. (C) Rheb1 mRNA
expression of AML cells. (D) PCR genotype of AML mice. (E) Histopathological
analysis of the spleens in AML mice. (F) Gating strategy for L-GMPs in the
spleen. (G) L-GMP frequency in the spleen (n = 4). (H) The percentages of
AML subpopulations in the spleen (n = 4). The data are the mean numbers
± SEM. Figure S3. The function and related signaling pathway of AML cells.
(A) GFP+ cells homing to the BM (left panel) and spleen (right panel), n = 5.
(B) The differentially expressed genes of AML cells. (C) Enrichment of M
phase mitotic cell cycle-related genes in GFP+ cells. (D and E) The cell cycle
status of K+G+ (D) and K−G+ cells (E) (n = 4). (F and G) The mRNA levels of
the indicated genes in GFP+ (F) and K+G− cells (G). The data are the mean
numbers ± SEM. (H and I) The normalized MFI of p-S6 (H) and p-4E-BP1 (I) of
K+G+ and K−G+ cells in the BM (n = 4). The data are the mean numbers ±
SEM. Figure S4. The signaling pathway in human and murine AML. (A and B)
mTOR (A) and 4E-BP1 (B) mRNA expression of human AML cells in the
HemaExplorer database. (C and D) KEGG analysis of the upregulated (C) and
downregulated (D) pathways in Rheb1Δ/Δ vs Rheb1fl/fl GFP+ cells. Table S1.
Primer sequence list. (PDF 30124 kb)
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